ATXA & PAH- Hope attend ERS Congress 2019 in Madrid
We’re here at the ERS Congress 2019 where we will be presenting the our preclinical findings of NTP42 for the treatment of PAH. Please...
top of page
- Sep 2, 2019
ATXA attends the ESC Congress 2019 in Paris
We're here! Drop by the Poster Area for the session on "Pulmonary Arterial Hypertension ‑ Treatments" and talk to us about our...
- Aug 26, 2019
ESC Congress Paris 2019
ATXA Therapeutics and PAH-Hope team members, Prof. Therese Kinsella & Dr. Helen Reid are looking forward to the ESC Congress 2019 next...
- Jul 22, 2019
Experimental and Molecular Pathology
Use the link below to read or download ATXA Therapeutics published article on the expression and regulation of thromboxane receptors in...
- Jul 9, 2019
New paper on thromboxane receptors in prostate inflammation published in Experimental and Molecular
ATXA Therapeutics, along with members of the academic research group of CSO Prof. Therese Kinsella at University College Dublin, have...
- May 23, 2019
EIC Welcomes Entrepreneurs
PAH-HOPE CSO Prof. Therese Kinsella is in Brussels meeting fellow entrepreneurs in the EIC community at SME Phase 2 Coordinators Welcome...
- May 7, 2019
- May 2, 2019
Funding Opportunities for Breakthrough Innovation
ATXA Therapeutics Founder and CSO, Prof Therese Kinsella will represent the company at an event on the European Innovation Council...
- May 2, 2019
Irish life sciences start-ups to watch
ATXA Therapeutics Ltd is proud to be listed among the 10 interesting Irish life sciences start-ups to watch. New hope for the PAH...
- Apr 8, 2019
Innovation Summit
The ATXA Therapeutics team is looking forward to attending the MedTech Strategist Innovation Summit Dublin 2019. 1 more day to go ! This...
- Mar 14, 2019
ATXA attends BioCapital Europe
ATXA Therapeutics is attending BioCapital Europe in Amterdam today. #Lifesciences #investment
COMPANY UPDATES
bottom of page